-

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Cutera, Inc. (CUTR)

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Cutera, Inc. (NASDAQ: CUTR) common stock between February 17, 2021 and May 9, 2023. Cutera is a medical aesthetic device company that provides equipment for beauty treatments.

For more information, submit a form, email Aaron Dumas, Jr., or give us a call (800) 350-6003.

What is this Case About: Cutera, Inc. (CUTR) Misled Investors Regarding its Internal Controls Over Financial Reporting

According to the complaint, throughout the class period, defendants repeatedly assured investors that the Company would deliver sustainable revenue growth in the wake of the COVID-19 pandemic while concealing that the Company maintained inadequate internal control over financial reporting and significant conflicts among certain members of the Company’s senior leadership and board of directors (the “Board”).

Beginning on January 9, 2023, investors began to learn the truth. On that day, the Company announced its failure to meet revenue guidance for 2022. On February 28, 2023, Cutera disclosed its inability to timely file its annual financial report with the SEC and that it had identified material weaknesses in its internal control over financial reporting. On March 16, 2023, Cutera announced it would not meet the extended deadline to file its annual report. Then, on March 24, 2023, Cutera disclosed its non-compliance with Nasdaq Listing Rule 5250(c)(1). Beginning on April 7, 2023, the Company disclosed conflicts with Board members. Finally, on May 9, 2023, Cutera revealed disappointing financial results for the first quarter 2023 “due to execution challenges in the business.” Each disclosure resulted in a decline in Cutera’s stock price, which ultimately closed at $14.14 per share on May 11, 2023.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Cutera, Inc. Shareholders who want to act as lead plaintiff for the class must file their papers by July 24, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Cutera, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:CUTR

Release Summary
Cutera, Inc. (CUTR) Misled Investors Regarding its Internal Controls Over Financial Reporting
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom